232 related articles for article (PubMed ID: 8382705)
1. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
Milovanovic SR; Monje E; Szepeshazi K; Radulovic S; Schally A
J Cancer Res Clin Oncol; 1993; 119(5):273-8. PubMed ID: 8382705
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
Milovanovic SR; Radulovic S; Schally AV
Breast Cancer Res Treat; 1992; 24(2):147-58. PubMed ID: 8443402
[TBL] [Abstract][Full Text] [Related]
3. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo.
Szepeshazi K; Schally AV; Juhasz A; Nagy A; Janaky T
Anticancer Drugs; 1992 Apr; 3(2):109-16. PubMed ID: 1388062
[TBL] [Abstract][Full Text] [Related]
4. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
[TBL] [Abstract][Full Text] [Related]
5. Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
Szepeshazi K; Schally AV; Halmos G; Szoke B; Groot K; Nagy A
Breast Cancer Res Treat; 1996; 40(2):129-39. PubMed ID: 8879679
[TBL] [Abstract][Full Text] [Related]
6. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
Szepeshazi K; Schally AV; Nagy A; Halmos G; Groot K
Anticancer Drugs; 1997 Nov; 8(10):974-87. PubMed ID: 9436641
[TBL] [Abstract][Full Text] [Related]
7. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.
Srkalovic G; Bokser L; Radulovic S; Korkut E; Schally AV
Endocrinology; 1990 Dec; 127(6):3052-60. PubMed ID: 2174343
[TBL] [Abstract][Full Text] [Related]
8. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on the function of rat pituitary cells: tests in a long term superfusion system.
Rékási Z; Szöke B; Nagy A; Groot K; Rékási ES; Schally AV
Endocrinology; 1993 May; 132(5):1991-2000. PubMed ID: 8477650
[TBL] [Abstract][Full Text] [Related]
9. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
Fekete M; Zalatnai A; Schally AV
Cancer Lett; 1989 May; 45(2):87-91. PubMed ID: 2567204
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals.
Pinski J; Schally AV; Yano T; Szepeshazi K; Halmos G; Groot K; Comaru-Schally AM; Radulovic S; Nagy A
Prostate; 1993; 23(2):165-78. PubMed ID: 8378189
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.
Fekete M; Wittliff JL; Schally AV
J Clin Lab Anal; 1989; 3(3):137-47. PubMed ID: 2569034
[TBL] [Abstract][Full Text] [Related]
13. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
Emons G; Schröder B; Ortmann O; Westphalen S; Schulz KD; Schally AV
J Clin Endocrinol Metab; 1993 Dec; 77(6):1458-64. PubMed ID: 8263128
[TBL] [Abstract][Full Text] [Related]
14. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
Kahán Z; Nagy A; Schally AV; Halmos G; Arencibia JM; Groot K
Breast Cancer Res Treat; 2000 Feb; 59(3):255-62. PubMed ID: 10832595
[TBL] [Abstract][Full Text] [Related]
15. Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.
Janáky T; Juhász A; Rékási Z; Serfözö P; Pinski J; Bokser L; Srkalovic G; Milovanovic S; Redding TW; Halmos G
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10203-7. PubMed ID: 1332035
[TBL] [Abstract][Full Text] [Related]
16. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
Yano T; Pinski J; Radulovic S; Schally AV
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868
[TBL] [Abstract][Full Text] [Related]
18. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
Kadar T; Redding TW; Ben-David M; Schally AV
Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
Halmos G; Schally AV; Kahan Z
Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
Redding TW; Schally AV
Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
